{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:46:59Z","timestamp":1793252819894,"version":"4.5.0"},"reference-count":260,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-025-10269-z","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T02:28:57Z","timestamp":1748485737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Novel immunotherapy for gastric cancer: targeting the CD47\u2013SIRP\u03b1 axis"],"prefix":"10.1007","volume":"44","author":[{"given":"Akira","family":"Ooki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Shimozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"10269_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin, 71, 209\u2013249.","journal-title":"CA: A Cancer J Clin"},{"key":"10269_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11894-017-0575-8","volume":"19","author":"M Balakrishnan","year":"2017","unstructured":"Balakrishnan, M., George, R., Sharma, A., & Graham, D. Y. (2017). Changing trends in stomach cancer throughout the world. Current Gastroenterology Rep, 19, 36.","journal-title":"Current Gastroenterology Rep"},{"key":"10269_CR3","unstructured":"The National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, Gastric Cancer. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf. 2024;version 5."},{"key":"10269_CR4","doi-asserted-by":"publisher","first-page":"102226","DOI":"10.1016\/j.esmoop.2023.102226","volume":"9","author":"K Shitara","year":"2024","unstructured":"Shitara, K., Fleitas, T., Kawakami, H., et al. (2024). Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ESMO Open., 9, 102226.","journal-title":"ESMO Open."},{"issue":"26","key":"10269_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","volume":"2023","author":"Japanese Gastric Cancer Treatment Guidelines","year":"2021","unstructured":"Japanese Gastric Cancer Treatment Guidelines. (2021). 6th edition. Gastric Cancer, 2023(26), 1\u201325.","journal-title":"Gastric Cancer"},{"key":"10269_CR6","doi-asserted-by":"crossref","unstructured":"Wagner, A. D., Syn, N. L., Moehler, M., et al. (2017). Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev, 8, Cd004064.","DOI":"10.1002\/14651858.CD004064.pub4"},{"key":"10269_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.23922\/jarc.2020-064","volume":"5","author":"A Ooki","year":"2021","unstructured":"Ooki, A., Shinozaki, E., & Yamaguchi, K. (2021). Immunotherapy in colorectal cancer: Current and future strategies. J Anus Rectum Colon., 5, 11\u201324.","journal-title":"J Anus Rectum Colon."},{"key":"10269_CR8","doi-asserted-by":"publisher","first-page":"175883592211383","DOI":"10.1177\/17588359221138377","volume":"15","author":"A Ooki","year":"2023","unstructured":"Ooki, A., Osumi, H., Chin, K., Watanabe, M., & Yamaguchi, K. (2023). Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma. Ther Adv Med Oncol., 15, 17588359221138376.","journal-title":"Ther Adv Med Oncol."},{"key":"10269_CR9","doi-asserted-by":"crossref","unstructured":"Ooki, A., Osumi, H., Yoshino, K., & Yamaguchi, K. (2024). Yamaguchi K. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and\/or deficient mismatch repair. Gastric Cancer.","DOI":"10.1007\/s10120-024-01523-4"},{"key":"10269_CR10","doi-asserted-by":"publisher","first-page":"175883592210830","DOI":"10.1177\/17588359221083049","volume":"14","author":"A Ooki","year":"2022","unstructured":"Ooki, A., & Yamaguchi, K. (2022). The dawn of precision medicine in diffuse-type gastric cancer. Ther Adv Med Oncol., 14, 17588359221083048.","journal-title":"Ther Adv Med Oncol."},{"key":"10269_CR11","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang, Y. K., Boku, N., Satoh, T., et al. (2017). Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 390, 2461\u20132471.","journal-title":"Lancet"},{"key":"10269_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020). A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nature Reviews Immunology, 20, 651\u2013668.","journal-title":"Nature Reviews Immunology"},{"key":"10269_CR13","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","volume":"174","author":"L Keren","year":"2018","unstructured":"Keren, L., Bosse, M., Marquez, D., et al. (2018). A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell, 174, 1373-1387.e1319.","journal-title":"Cell"},{"key":"10269_CR14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41556-019-0373-7","volume":"21","author":"IS Kim","year":"2019","unstructured":"Kim, I. S., Gao, Y., Welte, T., et al. (2019). Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nature Cell Biology, 21, 1113\u20131126.","journal-title":"Nature Cell Biology"},{"key":"10269_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","volume":"19","author":"MJ Pittet","year":"2022","unstructured":"Pittet, M. J., Michielin, O., & Migliorini, D. (2022). Clinical relevance of tumour-associated macrophages. Nature Reviews. Clinical Oncology, 19, 402\u2013421.","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10269_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022). Macrophages as tools and targets in cancer therapy. Nature Reviews. Drug Discovery, 21, 799\u2013820.","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10269_CR17","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham, S. B., Volkmer, J. P., Gentles, A. J., et al. (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A., 109, 6662\u20136667.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10269_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12527","volume":"276","author":"HL Matlung","year":"2017","unstructured":"Matlung, H. L., Szilagyi, K., Barclay, N. A., & van den Berg, T. K. (2017). The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer. Immunological Reviews, 276, 145\u2013164.","journal-title":"Immunological Reviews"},{"key":"10269_CR19","doi-asserted-by":"publisher","first-page":"e2304943120","DOI":"10.1073\/pnas.2304943120","volume":"120","author":"S Komori","year":"2023","unstructured":"Komori, S., Saito, Y., Nishimura, T., et al. (2023). CD47 promotes peripheral T cell survival by preventing dendritic cell-mediated T cell necroptosis. Proc Natl Acad Sci U S A., 120, e2304943120.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10269_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","volume":"19","author":"M Feng","year":"2019","unstructured":"Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y. X., & Weissman, I. L. (2019). Phagocytosis checkpoints as new targets for cancer immunotherapy. Nature Reviews Cancer, 19, 568\u2013586.","journal-title":"Nature Reviews Cancer"},{"key":"10269_CR21","doi-asserted-by":"publisher","first-page":"350","DOI":"10.7150\/jca.80725","volume":"14","author":"Z Liu","year":"2023","unstructured":"Liu, Z., Chen, H., Ta, N., et al. (2023). Anti-CD47 antibody enhances the efficacy of chemotherapy in patients with gastric cancer liver metastasis. Journal of Cancer, 14, 350\u2013359.","journal-title":"Journal of Cancer"},{"key":"10269_CR22","doi-asserted-by":"publisher","first-page":"11103","DOI":"10.1073\/pnas.1305569110","volume":"110","author":"D Tseng","year":"2013","unstructured":"Tseng, D., Volkmer, J. P., Willingham, S. B., et al. (2013). Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A., 110, 11103\u201311108.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10269_CR23","doi-asserted-by":"publisher","first-page":"E2646","DOI":"10.1073\/pnas.1604268113","volume":"113","author":"JT Sockolosky","year":"2016","unstructured":"Sockolosky, J. T., Dougan, M., Ingram, J. R., et al. (2016). Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A., 113, E2646-2654.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10269_CR24","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/s41467-020-15129-8","volume":"11","author":"CA von Roemeling","year":"2020","unstructured":"von Roemeling, C. A., Wang, Y., Qie, Y., et al. (2020). Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nature Communications, 11, 1508.","journal-title":"Nature Communications"},{"key":"10269_CR25","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1200\/JCO.2025.43.4_suppl.332","volume":"43","author":"KWZ Shitara","year":"2025","unstructured":"Shitara, K. W. Z., Tabernero, J., et al. (2025). Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2\/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric\/gastroesophageal cancer (GC). Journal of Clinical Oncology, 43, 332.","journal-title":"Journal of Clinical Oncology"},{"key":"10269_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1126\/science.1183021","volume":"327","author":"A Iwasaki","year":"2010","unstructured":"Iwasaki, A., & Medzhitov, R. (2010). Regulation of adaptive immunity by the innate immune system. Science, 327, 291\u2013295.","journal-title":"Science"},{"key":"10269_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1146\/annurev.cellbio.20.010403.102755","volume":"21","author":"I Jutras","year":"2005","unstructured":"Jutras, I., & Desjardins, M. (2005). Phagocytosis: At the crossroads of innate and adaptive immunity. Annual Review of Cell and Developmental Biology, 21, 511\u2013527.","journal-title":"Annual Review of Cell and Developmental Biology"},{"key":"10269_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature12034","volume":"496","author":"TA Wynn","year":"2013","unstructured":"Wynn, T. A., Chawla, A., & Pollard, J. W. (2013). Macrophage biology in development, homeostasis and disease. Nature, 496, 445\u2013455.","journal-title":"Nature"},{"key":"10269_CR29","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","volume":"21","author":"X Liu","year":"2015","unstructured":"Liu, X., Pu, Y., Cron, K., et al. (2015). CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nature Medicine, 21, 1209\u20131215.","journal-title":"Nature Medicine"},{"key":"10269_CR30","doi-asserted-by":"crossref","unstructured":"Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., et al. (2010). Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med, 2, 63ra94.","DOI":"10.1126\/scitranslmed.3001375"},{"key":"10269_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","volume":"32","author":"AN Barclay","year":"2014","unstructured":"Barclay, A. N., & Van den Berg, T. K. (2014). The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: Structure, function, and therapeutic target. Annual Review of Immunology, 32, 25\u201350.","journal-title":"Annual Review of Immunology"},{"key":"10269_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1083\/jcb.200708043","volume":"180","author":"RK Tsai","year":"2008","unstructured":"Tsai, R. K., & Discher, D. E. (2008). Inhibition of \u201cself\u201d engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. Journal of Cell Biology, 180, 989\u20131003.","journal-title":"Journal of Cell Biology"},{"key":"10269_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/386181a0","volume":"386","author":"A Kharitonenkov","year":"1997","unstructured":"Kharitonenkov, A., Chen, Z., Sures, I., Wang, H., Schilling, J., & Ullrich, A. (1997). A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature, 386, 181\u2013186.","journal-title":"Nature"},{"key":"10269_CR34","doi-asserted-by":"crossref","unstructured":"Li, Y., Zhou, H., Liu, P., et al. (2023). SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47\/SIRP\u03b1 axis. J Clin Invest, 133.","DOI":"10.1172\/JCI162870"},{"key":"10269_CR35","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1182\/blood.V94.11.3633","volume":"94","author":"M Seiffert","year":"1999","unstructured":"Seiffert, M., Cant, C., Chen, Z., et al. (1999). Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood, 94, 3633\u20133643.","journal-title":"Blood"},{"key":"10269_CR36","doi-asserted-by":"publisher","first-page":"12397","DOI":"10.1523\/JNEUROSCI.3981-06.2006","volume":"26","author":"T Murata","year":"2006","unstructured":"Murata, T., Ohnishi, H., Okazawa, H., et al. (2006). CD47 promotes neuronal development through Src- and FRG\/Vav2-mediated activation of Rac and Cdc42. Journal of Neuroscience, 26, 12397\u201312407.","journal-title":"Journal of Neuroscience"},{"key":"10269_CR37","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.4049\/jimmunol.161.4.1853","volume":"161","author":"S Adams","year":"1998","unstructured":"Adams, S., van der Laan, L. J., Vernon-Wilson, E., et al. (1998). Signal-regulatory protein is selectively expressed by myeloid and neuronal cells. The Journal of Immunology, 161, 1853\u20131859.","journal-title":"The Journal of Immunology"},{"key":"10269_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-021-00571-6","volume":"22","author":"CC Hedrick","year":"2022","unstructured":"Hedrick, C. C., & Malanchi, I. (2022). Neutrophils in cancer: Heterogeneous and multifaceted. Nature Reviews Immunology, 22, 173\u2013187.","journal-title":"Nature Reviews Immunology"},{"key":"10269_CR39","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1084\/jem.20062611","volume":"204","author":"XN Kong","year":"2007","unstructured":"Kong, X. N., Yan, H. X., Chen, L., et al. (2007). LPS-induced down-regulation of signal regulatory protein alpha contributes to innate immune activation in macrophages. Journal of Experimental Medicine, 204, 2719\u20132731.","journal-title":"Journal of Experimental Medicine"},{"key":"10269_CR40","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.molimm.2008.03.012","volume":"45","author":"LW Dong","year":"2008","unstructured":"Dong, L. W., Kong, X. N., Yan, H. X., et al. (2008). Signal regulatory protein alpha negatively regulates both TLR3 and cytoplasmic pathways in type I interferon induction. Molecular Immunology, 45, 3025\u20133035.","journal-title":"Molecular Immunology"},{"key":"10269_CR41","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1038\/ncomms3436","volume":"4","author":"K Zen","year":"2013","unstructured":"Zen, K., Guo, Y., Bian, Z., et al. (2013). Inflammation-induced proteolytic processing of the SIRP\u03b1 cytoplasmic ITIM in neutrophils propagates a proinflammatory state. Nature Communications, 4, 2436.","journal-title":"Nature Communications"},{"key":"10269_CR42","doi-asserted-by":"publisher","first-page":"31113","DOI":"10.1074\/jbc.M115.682914","volume":"290","author":"JD Londino","year":"2015","unstructured":"Londino, J. D., Gulick, D., Isenberg, J. S., & Mallampalli, R. K. (2015). Cleavage of signal regulatory protein \u03b1 (SIRP\u03b1) enhances inflammatory signaling. Journal of Biological Chemistry, 290, 31113\u201331125.","journal-title":"Journal of Biological Chemistry"},{"key":"10269_CR43","doi-asserted-by":"crossref","unstructured":"Uhl\u00e9n, M., Fagerberg, L., Hallstr\u00f6m, B. M., et al. (2015). Proteomics. Tissue-based map of the human proteome. Science, 347, 1260419.","DOI":"10.1126\/science.347.6227.1274-c"},{"key":"10269_CR44","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41467-019-08637-9","volume":"10","author":"LM Myers","year":"2019","unstructured":"Myers, L. M., Tal, M. C., Torrez Dulgeroff, L. B., et al. (2019). A functional subset of CD8(+) T cells during chronic exhaustion is defined by SIRP\u03b1 expression. Nature Communications, 10, 794.","journal-title":"Nature Communications"},{"key":"10269_CR45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nri1859","volume":"6","author":"AN Barclay","year":"2006","unstructured":"Barclay, A. N., & Brown, M. H. (2006). The SIRP family of receptors and immune regulation. Nature Reviews Immunology, 6, 457\u2013464.","journal-title":"Nature Reviews Immunology"},{"key":"10269_CR46","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.4049\/jimmunol.173.4.2562","volume":"173","author":"G Brooke","year":"2004","unstructured":"Brooke, G., Holbrook, J. D., Brown, M. H., & Barclay, A. N. (2004). Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family. The Journal of Immunology, 173, 2562\u20132570.","journal-title":"The Journal of Immunology"},{"key":"10269_CR47","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"PA Oldenborg","year":"2000","unstructured":"Oldenborg, P. A., Zheleznyak, A., Fang, Y. F., Lagenaur, C. F., Gresham, H. D., & Lindberg, F. P. (2000). Role of CD47 as a marker of self on red blood cells. Science, 288, 2051\u20132054.","journal-title":"Science"},{"key":"10269_CR48","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1182\/blood-2004-08-2980","volume":"105","author":"M Olsson","year":"2005","unstructured":"Olsson, M., Bruhns, P., Frazier, W. A., Ravetch, J. V., & Oldenborg, P. A. (2005). Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood, 105, 3577\u20133582.","journal-title":"Blood"},{"key":"10269_CR49","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey, S. C., Tong, L., Li, Y., et al. (2016). MYC regulates the antitumor immune response through CD47 and PD-L1. Science, 352, 227\u2013231.","journal-title":"Science"},{"key":"10269_CR50","doi-asserted-by":"publisher","first-page":"E6215","DOI":"10.1073\/pnas.1520032112","volume":"112","author":"H Zhang","year":"2015","unstructured":"Zhang, H., Lu, H., Xiang, L., et al. (2015). HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci U S A., 112, E6215-6223.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10269_CR51","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nature14321","volume":"522","author":"BD Berkovits","year":"2015","unstructured":"Berkovits, B. D., & Mayr, C. (2015). Alternative 3\u2032 UTRs act as scaffolds to regulate membrane protein localization. Nature, 522, 363\u2013367.","journal-title":"Nature"},{"key":"10269_CR52","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3892\/or.2012.1831","volume":"28","author":"S Suzuki","year":"2012","unstructured":"Suzuki, S., Yokobori, T., Tanaka, N., et al. (2012). CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncology Reports, 28, 465\u2013472.","journal-title":"Oncology Reports"},{"key":"10269_CR53","doi-asserted-by":"publisher","first-page":"43712","DOI":"10.18632\/oncotarget.6227","volume":"6","author":"SY Yang","year":"2015","unstructured":"Yang, S. Y., Choi, S. A., Lee, J. Y., et al. (2015). miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR, integrins, and CD47. Oncotarget, 6, 43712\u201343730.","journal-title":"Oncotarget"},{"key":"10269_CR54","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/carcin\/bgad061","volume":"44","author":"G Kang","year":"2023","unstructured":"Kang, G., Jiao, Y., Pan, P., et al. (2023). \u03b15-nAChR\/STAT3\/CD47 axis contributed to nicotine-related lung adenocarcinoma progression and immune escape. Carcinogenesis, 44, 773\u2013784.","journal-title":"Carcinogenesis"},{"key":"10269_CR55","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1200\/JCO.2023.41.4_suppl.240","volume":"41","author":"H Arai","year":"2023","unstructured":"Arai, H., Gandhi, N., Battaglin, F., et al. (2023). The role of gene expression of CD47 in colorectal cancer (CRC). Journal of Clinical Oncology., 41, 240\u2013240.","journal-title":"Journal of Clinical Oncology."},{"key":"10269_CR56","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3389\/fonc.2020.01525","volume":"10","author":"Y Liu","year":"2020","unstructured":"Liu, Y., Chang, Y., He, X., et al. (2020). CD47 enhances cell viability and migration ability but inhibits apoptosis in endometrial carcinoma cells via the PI3K\/Akt\/mTOR signaling pathway. Frontiers in Oncology, 10, 1525.","journal-title":"Frontiers in Oncology"},{"key":"10269_CR57","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/s41467-022-29137-3","volume":"13","author":"N Jiang","year":"2022","unstructured":"Jiang, N., Xie, B., Xiao, W., et al. (2022). Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nature Communications, 13, 1511.","journal-title":"Nature Communications"},{"key":"10269_CR58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4161\/cc.10.1.14324","volume":"10","author":"S Kaur","year":"2011","unstructured":"Kaur, S., & Roberts, D. D. (2011). CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2. Cell Cycle, 10, 10\u201312.","journal-title":"Cell Cycle"},{"key":"10269_CR59","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon, S. R., Maute, R. L., Dulken, B. W., et al. (2017). PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature, 545, 495\u2013499.","journal-title":"Nature"},{"key":"10269_CR60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy, R., & Pollard, J. W. (2014). Tumor-associated macrophages: From mechanisms to therapy. Immunity, 41, 49\u201361.","journal-title":"Immunity"},{"key":"10269_CR61","doi-asserted-by":"publisher","first-page":"e0153550","DOI":"10.1371\/journal.pone.0153550","volume":"11","author":"M Zhang","year":"2016","unstructured":"Zhang, M., Hutter, G., Kahn, S. A., et al. (2016). Anti-CD47 Treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo. PLoS ONE, 11, e0153550.","journal-title":"PLoS ONE"},{"key":"10269_CR62","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1158\/1078-0432.CCR-21-1248","volume":"28","author":"L Tian","year":"2022","unstructured":"Tian, L., Xu, B., Teng, K. Y., et al. (2022). Targeting Fc receptor-mediated effects and the \u201cDon\u2019t Eat Me\u201d signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer. Clinical Cancer Research, 28, 201\u2013214.","journal-title":"Clinical Cancer Research"},{"key":"10269_CR63","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00262-020-02806-2","volume":"70","author":"M Shi","year":"2021","unstructured":"Shi, M., Gu, Y., Jin, K., et al. (2021). CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. Cancer Immunology, Immunotherapy, 70, 1831\u20131840.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10269_CR64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00262-024-03667-9","volume":"73","author":"K Zhang","year":"2024","unstructured":"Zhang, K., Xu, Y., Chang, X., et al. (2024). Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer. Cancer Immunology, Immunotherapy, 73, 75.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10269_CR65","doi-asserted-by":"publisher","first-page":"22406","DOI":"10.18632\/oncotarget.9899","volume":"8","author":"L Gao","year":"2017","unstructured":"Gao, L., Chen, K., Gao, Q., Wang, X., Sun, J., & Yang, Y. G. (2017). CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis. Oncotarget, 8, 22406\u201322413.","journal-title":"Oncotarget"},{"key":"10269_CR66","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.4049\/jimmunol.168.11.5832","volume":"168","author":"HE de Vries","year":"2002","unstructured":"de Vries, H. E., Hendriks, J. J., Honing, H., et al. (2002). Signal-regulatory protein alpha-CD47 interactions are required for the transmigration of monocytes across cerebral endothelium. The Journal of Immunology, 168, 5832\u20135839.","journal-title":"The Journal of Immunology"},{"key":"10269_CR67","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1111\/ajt.15497","volume":"19","author":"S Pengam","year":"2019","unstructured":"Pengam, S., Durand, J., Usal, C., et al. (2019). SIRP\u03b1\/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid-derived suppressor cells. American Journal of Transplantation, 19, 3263\u20133275.","journal-title":"American Journal of Transplantation"},{"key":"10269_CR68","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.3389\/fimmu.2018.02985","volume":"9","author":"PR Nath","year":"2018","unstructured":"Nath, P. R., Gangaplara, A., Pal-Nath, D., et al. (2018). CD47 expression in natural killer cells regulates homeostasis and modulates immune response to lymphocytic choriomeningitis virus. Frontiers in Immunology, 9, 2985.","journal-title":"Frontiers in Immunology"},{"key":"10269_CR69","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1158\/2326-6066.CIR-18-0367","volume":"7","author":"PR Nath","year":"2019","unstructured":"Nath, P. R., Pal-Nath, D., Mandal, A., Cam, M. C., Schwartz, A. L., & Roberts, D. D. (2019). Natural killer cell recruitment and activation are regulated by CD47 expression in the tumor microenvironment. Cancer Immunology Research, 7, 1547\u20131561.","journal-title":"Cancer Immunology Research"},{"key":"10269_CR70","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1158\/0008-5472.CAN-18-3125","volume":"79","author":"D Ma","year":"2019","unstructured":"Ma, D., Liu, S., Lal, B., et al. (2019). Extracellular matrix protein tenascin C increases phagocytosis mediated by CD47 loss of function in glioblastoma. Cancer Research, 79, 2697\u20132708.","journal-title":"Cancer Research"},{"key":"10269_CR71","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3892\/ol.2017.6257","volume":"14","author":"T Sudo","year":"2017","unstructured":"Sudo, T., Takahashi, Y., Sawada, G., Uchi, R., Mimori, K., & Akagi, Y. (2017). Significance of CD47 expression in gastric cancer. Oncology Letters, 14, 801\u2013809.","journal-title":"Oncology Letters"},{"key":"10269_CR72","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.2174\/0929867311209065975","volume":"19","author":"W Hoffmann","year":"2012","unstructured":"Hoffmann, W. (2012). Stem cells, self-renewal and cancer of the gastric epithelium. Current Medicinal Chemistry, 19, 5975\u20135983.","journal-title":"Current Medicinal Chemistry"},{"key":"10269_CR73","first-page":"550","volume":"3","author":"A Gupta","year":"2020","unstructured":"Gupta, A., Taslim, C., Tullius, B. P., & Cripe, T. P. (2020). Therapeutic modulation of the CD47-SIRP\u03b1 axis in the pediatric tumor microenvironment: Working up an appetite. Cancer Drug Resist., 3, 550\u2013562.","journal-title":"Cancer Drug Resist."},{"key":"10269_CR74","doi-asserted-by":"publisher","first-page":"16609","DOI":"10.1007\/s00432-023-05408-4","volume":"149","author":"S Chen","year":"2023","unstructured":"Chen, S., Zhan, S., Ding, S., et al. (2023). B7\u2013H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy. Journal of Cancer Research and Clinical Oncology, 149, 16609\u201316621.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10269_CR75","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/cam4.478","volume":"4","author":"K Yoshida","year":"2015","unstructured":"Yoshida, K., Tsujimoto, H., Matsumura, K., et al. (2015). CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Medicine, 4, 1322\u20131333.","journal-title":"Cancer Medicine"},{"key":"10269_CR76","doi-asserted-by":"publisher","first-page":"e13198","DOI":"10.1111\/sji.13198","volume":"96","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y., Zeng, J., Zhou, W., Wu, K., Tian, Z., & Shen, W. (2022). Prognostic significance of CKS2 and CD47 expression in patients with gastric cancer who underwent radical gastrectomy. Scandinavian Journal of Immunology, 96, e13198.","journal-title":"Scandinavian Journal of Immunology"},{"key":"10269_CR77","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1158\/0008-5472.CAN-23-0783","volume":"83","author":"Y Fan","year":"2023","unstructured":"Fan, Y., Song, S., Li, Y., et al. (2023). Galectin-3 cooperates with CD47 to suppress phagocytosis and T-cell immunity in gastric cancer peritoneal metastases. Cancer Research, 83, 3726\u20133738.","journal-title":"Cancer Research"},{"key":"10269_CR78","doi-asserted-by":"crossref","unstructured":"Arai, H., Gandhi, N., Battaglin, F., et al. (2024). Role of CD47 gene expression in colorectal cancer: A comprehensive molecular profiling study. J Immunother Cancer, 12.","DOI":"10.1136\/jitc-2024-010326"},{"key":"10269_CR79","doi-asserted-by":"publisher","first-page":"109238","DOI":"10.1016\/j.clim.2023.109238","volume":"247","author":"Y Duan","year":"2023","unstructured":"Duan, Y., Li, S., Huang, B., et al. (2023). CD47-targeted immunotherapy unleashes antitumour immunity in Epstein-Barr virus-associated gastric cancer. Clinical Immunology, 247, 109238.","journal-title":"Clinical Immunology"},{"key":"10269_CR80","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00428-018-2332-2","volume":"472","author":"H Abe","year":"2018","unstructured":"Abe, H., Saito, R., Ichimura, T., et al. (2018). CD47 expression in Epstein-Barr virus-associated gastric carcinoma: Coexistence with tumor immunity lowering the ratio of CD8(+)\/Foxp3(+) T cells. Virchows Archiv, 472, 643\u2013651.","journal-title":"Virchows Archiv"},{"key":"10269_CR81","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"CGAR Network","year":"2014","unstructured":"Network, C. G. A. R. (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 513, 202\u2013209.","journal-title":"Nature"},{"key":"10269_CR82","doi-asserted-by":"publisher","first-page":"745120","DOI":"10.3389\/fcell.2021.745120","volume":"9","author":"Q Zhao","year":"2021","unstructured":"Zhao, Q., Cai, Q., Yu, S., et al. (2021). Combinatorial analysis of AT-rich interaction domain 1A and CD47 in gastric cancer patients reveals markers of prognosis. Front Cell Dev Biol., 9, 745120.","journal-title":"Front Cell Dev Biol."},{"key":"10269_CR83","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/ng.982","volume":"43","author":"K Wang","year":"2011","unstructured":"Wang, K., Kan, J., Yuen, S. T., et al. (2011). Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nature Genetics, 43, 1219\u20131223.","journal-title":"Nature Genetics"},{"key":"10269_CR84","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu, R., Lee, J., Nebozhyn, M., et al. (2015). Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature Medicine, 21, 449\u2013456.","journal-title":"Nature Medicine"},{"key":"10269_CR85","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","volume":"3","author":"MV Dieci","year":"2013","unstructured":"Dieci, M. V., Arnedos, M., Andre, F., & Soria, J. C. (2013). Fibroblast growth factor receptor inhibitors as a cancer treatment: From a biologic rationale to medical perspectives. Cancer Discovery, 3, 264\u2013279.","journal-title":"Cancer Discovery"},{"key":"10269_CR86","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10120-021-01235-z","volume":"24","author":"A Ooki","year":"2021","unstructured":"Ooki, A., & Yamaguchi, K. (2021). The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration. Gastric Cancer, 24, 1169\u20131183.","journal-title":"Gastric Cancer"},{"key":"10269_CR87","doi-asserted-by":"publisher","first-page":"167821","DOI":"10.1016\/j.bbadis.2025.167821","volume":"1871","author":"F Albano","year":"2025","unstructured":"Albano, F., Severini, F. L., Calice, G., Zoppoli, P., Falco, G., & Notarangelo, T. (2025). The role of the tumor microenvironment and inflammatory pathways in driving drug resistance in gastric cancer: A systematic review and meta-analysis. Biochimica et Biophysica Acta, Molecular Basis of Disease, 1871, 167821.","journal-title":"Biochimica et Biophysica Acta, Molecular Basis of Disease"},{"key":"10269_CR88","doi-asserted-by":"publisher","first-page":"803974","DOI":"10.3389\/fonc.2021.803974","volume":"11","author":"Y Yang","year":"2021","unstructured":"Yang, Y., Meng, W. J., & Wang, Z. Q. (2021). Cancer stem cells and the tumor microenvironment in gastric cancer. Frontiers in Oncology, 11, 803974.","journal-title":"Frontiers in Oncology"},{"key":"10269_CR89","doi-asserted-by":"crossref","unstructured":"Yun, H., Dong, F., Wei, X., et al. (2025). Role and value of the tumor microenvironment in the progression and treatment resistance of gastric cancer (Review). Oncol Rep, 53.","DOI":"10.3892\/or.2024.8847"},{"key":"10269_CR90","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1111\/cas.14521","volume":"111","author":"Y Oya","year":"2020","unstructured":"Oya, Y., Hayakawa, Y., & Koike, K. (2020). Tumor microenvironment in gastric cancers. Cancer Science, 111, 2696\u20132707.","journal-title":"Cancer Science"},{"key":"10269_CR91","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13046-018-1003-0","volume":"38","author":"S Li","year":"2019","unstructured":"Li, S., Cong, X., Gao, H., et al. (2019). Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells. Journal of Experimental & Clinical Cancer Research, 38, 6.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10269_CR92","doi-asserted-by":"publisher","first-page":"e1295","DOI":"10.1038\/cddis.2014.263","volume":"5","author":"Q Zhu","year":"2014","unstructured":"Zhu, Q., Zhang, X., Zhang, L., et al. (2014). The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression. Cell Death & Disease, 5, e1295.","journal-title":"Cell Death & Disease"},{"key":"10269_CR93","doi-asserted-by":"publisher","first-page":"115405","DOI":"10.1016\/j.biopha.2023.115405","volume":"166","author":"T Liu","year":"2023","unstructured":"Liu, T., Guo, S., Ji, Y., & Zhu, W. (2023). Role of cancer-educated mesenchymal stromal cells on tumor progression. Biomedicine & Pharmacotherapy, 166, 115405.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10269_CR94","doi-asserted-by":"publisher","first-page":"e484","DOI":"10.1002\/ctm2.484","volume":"11","author":"ZG Shan","year":"2021","unstructured":"Shan, Z. G., Chen, J., Liu, J. S., et al. (2021). Activated neutrophils polarize protumorigenic interleukin-17A-producing T helper subsets through TNF-\u03b1-B7-H2-dependent pathway in human gastric cancer. Clinical and Translational Medicine, 11, e484.","journal-title":"Clinical and Translational Medicine"},{"key":"10269_CR95","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s10120-023-01456-4","volume":"27","author":"C Tsutsumi","year":"2024","unstructured":"Tsutsumi, C., Ohuchida, K., Katayama, N., et al. (2024). Tumor-infiltrating monocytic myeloid-derived suppressor cells contribute to the development of an immunosuppressive tumor microenvironment in gastric cancer. Gastric Cancer, 27, 248\u2013262.","journal-title":"Gastric Cancer"},{"key":"10269_CR96","doi-asserted-by":"publisher","first-page":"215598","DOI":"10.1016\/j.canlet.2022.215598","volume":"532","author":"X Zhou","year":"2022","unstructured":"Zhou, X., Fang, D., Liu, H., et al. (2022). PMN-MDSCs accumulation induced by CXCL1 promotes CD8(+) T cells exhaustion in gastric cancer. Cancer Letters, 532, 215598.","journal-title":"Cancer Letters"},{"key":"10269_CR97","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s41419-022-05320-8","volume":"13","author":"H Sun","year":"2022","unstructured":"Sun, H., Wang, X., Wang, X., Xu, M., & Sheng, W. (2022). The role of cancer-associated fibroblasts in tumorigenesis of gastric cancer. Cell Death & Disease, 13, 874.","journal-title":"Cell Death & Disease"},{"key":"10269_CR98","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/ijc.33873","volume":"150","author":"Y Qu","year":"2022","unstructured":"Qu, Y., Wang, X., Bai, S., et al. (2022). The effects of TNF-\u03b1\/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer. International Journal of Cancer, 150, 1373\u20131391.","journal-title":"International Journal of Cancer"},{"key":"10269_CR99","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.7150\/jca.49707","volume":"12","author":"Y Qin","year":"2021","unstructured":"Qin, Y., Wang, F., Ni, H., et al. (2021). Cancer-associated fibroblasts in gastric cancer affect malignant progression via the CXCL12-CXCR4 axis. Journal of Cancer, 12, 3011\u20133023.","journal-title":"Journal of Cancer"},{"key":"10269_CR100","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s10120-015-0584-y","volume":"20","author":"A Abe","year":"2017","unstructured":"Abe, A., Nagatsuma, A. K., Higuchi, Y., Nakamura, Y., Yanagihara, K., & Ochiai, A. (2017). Site-specific fibroblasts regulate site-specific inflammatory niche formation in gastric cancer. Gastric Cancer, 20, 92\u2013103.","journal-title":"Gastric Cancer"},{"key":"10269_CR101","doi-asserted-by":"publisher","first-page":"105937","DOI":"10.1016\/j.intimp.2019.105937","volume":"78","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y., Cong, X., Li, Z., & Xue, Y. (2020). Estrogen facilitates gastric cancer cell proliferation and invasion through promoting the secretion of interleukin-6 by cancer-associated fibroblasts. International Immunopharmacology, 78, 105937.","journal-title":"International Immunopharmacology"},{"key":"10269_CR102","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1158\/2159-8290.CD-21-0219","volume":"11","author":"M Kwon","year":"2021","unstructured":"Kwon, M., An, M., Klempner, S. J., et al. (2021). Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer. Cancer Discovery, 11, 2168\u20132185.","journal-title":"Cancer Discovery"},{"key":"10269_CR103","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3324\/haematol.2010.023689","volume":"95","author":"A Merlo","year":"2010","unstructured":"Merlo, A., Turrini, R., Dolcetti, R., et al. (2010). The interplay between Epstein-Barr virus and the immune system: A rationale for adoptive cell therapy of EBV-related disorders. Haematologica, 95, 1769\u20131777.","journal-title":"Haematologica"},{"key":"10269_CR104","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/bjc.2011.330","volume":"105","author":"Y Fuyuhiro","year":"2011","unstructured":"Fuyuhiro, Y., Yashiro, M., Noda, S., et al. (2011). Upregulation of cancer-associated myofibroblasts by TGF-\u03b2 from scirrhous gastric carcinoma cells. British Journal of Cancer, 105, 996\u20131001.","journal-title":"British Journal of Cancer"},{"key":"10269_CR105","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1002\/ijc.28520","volume":"134","author":"T Hasegawa","year":"2014","unstructured":"Hasegawa, T., Yashiro, M., Nishii, T., et al. (2014). Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-\u03b2 signaling. International Journal of Cancer, 134, 1785\u20131795.","journal-title":"International Journal of Cancer"},{"key":"10269_CR106","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/15233","volume":"5","author":"V Mateo","year":"1999","unstructured":"Mateo, V., Lagneaux, L., Bron, D., et al. (1999). CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nature Medicine, 5, 1277\u20131284.","journal-title":"Nature Medicine"},{"key":"10269_CR107","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao, M. P., Alizadeh, A. A., Tang, C., et al. (2010). Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell, 142, 699\u2013713.","journal-title":"Cell"},{"key":"10269_CR108","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal, S., Jamieson, C. H., Pang, W. W., et al. (2009). CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell, 138, 271\u2013285.","journal-title":"Cell"},{"key":"10269_CR109","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti, R., Chao, M. P., Alizadeh, A. A., et al. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell, 138, 286\u2013299.","journal-title":"Cell"},{"key":"10269_CR110","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI81603","volume":"126","author":"K Weiskopf","year":"2016","unstructured":"Weiskopf, K., Jahchan, N. S., Schnorr, P. J., et al. (2016). CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. The Journal of Clinical Investigation, 126, 2610\u20132620.","journal-title":"The Journal of Clinical Investigation"},{"key":"10269_CR111","doi-asserted-by":"publisher","first-page":"e1183850","DOI":"10.1080\/2162402X.2016.1183850","volume":"5","author":"Q Liu","year":"2016","unstructured":"Liu, Q., Wen, W., Tang, L., et al. (2016). Inhibition of SIRP\u03b1 in dendritic cells potentiates potent antitumor immunity. Oncoimmunology., 5, e1183850.","journal-title":"Oncoimmunology."},{"key":"10269_CR112","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13045-022-01385-2","volume":"15","author":"J Yu","year":"2022","unstructured":"Yu, J., Li, S., Chen, D., et al. (2022). SIRP\u03b1-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47\/SIRP\u03b1 signal pathway via blocking the \u201cdon\u2019t eat me\u201d signal and activating the \u201ceat me\u201d signal. Journal of Hematology & Oncology, 15, 167.","journal-title":"Journal of Hematology & Oncology"},{"key":"10269_CR113","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1158\/0008-5472.CAN-14-0037-T","volume":"74","author":"DR Soto-Pantoja","year":"2014","unstructured":"Soto-Pantoja, D. R., Terabe, M., Ghosh, A., et al. (2014). CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Research, 74, 6771\u20136783.","journal-title":"Cancer Research"},{"key":"10269_CR114","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","volume":"39","author":"A Veillette","year":"2018","unstructured":"Veillette, A., & Chen, J. (2018). SIRP\u03b1-CD47 Immune checkpoint blockade in anticancer therapy. Trends in Immunology, 39, 173\u2013184.","journal-title":"Trends in Immunology"},{"key":"10269_CR115","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.immuni.2017.07.016","volume":"47","author":"MM Xu","year":"2017","unstructured":"Xu, M. M., Pu, Y., Han, D., et al. (2017). Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein \u03b1 signaling. Immunity, 47, 363-373.e365.","journal-title":"Immunity"},{"key":"10269_CR116","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn, F., & Ravetch, J. V. (2008). Fcgamma receptors as regulators of immune responses. Nature Reviews Immunology, 8, 34\u201347.","journal-title":"Nature Reviews Immunology"},{"key":"10269_CR117","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1158\/0008-5472.CAN-15-1330","volume":"75","author":"N G\u00fcl","year":"2015","unstructured":"G\u00fcl, N., & van Egmond, M. (2015). Antibody-dependent phagocytosis of tumor cells by macrophages: A potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Research, 75, 5008\u20135013.","journal-title":"Cancer Research"},{"key":"10269_CR118","doi-asserted-by":"publisher","first-page":"5908","DOI":"10.1038\/s41467-021-26003-6","volume":"12","author":"B Xu","year":"2021","unstructured":"Xu, B., Tian, L., Chen, J., et al. (2021). An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. Nature Communications, 12, 5908.","journal-title":"Nature Communications"},{"key":"10269_CR119","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.22.01794","volume":"41","author":"DA Sallman","year":"2023","unstructured":"Sallman, D. A., Al Malki, M. M., Asch, A. S., et al. (2023). Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: Final results of a phase Ib study. Journal of Clinical Oncology, 41, 2815\u20132826.","journal-title":"Journal of Clinical Oncology"},{"key":"10269_CR120","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1200\/JCO.22.02604","volume":"41","author":"NG Daver","year":"2023","unstructured":"Daver, N. G., Vyas, P., Kambhampati, S., et al. (2023). Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: Phase Ib results. Journal of Clinical Oncology, 41, 4893\u20134904.","journal-title":"Journal of Clinical Oncology"},{"key":"10269_CR121","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood-2021-153638","volume":"138","author":"N Daver","year":"2021","unstructured":"Daver, N., Konopleva, M., Maiti, A., et al. (2021). Phase I\/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed older\/unfit or high-risk acute myeloid leukemia (AML) and relapsed\/refractory (R\/R) AML. Blood, 138, 371.","journal-title":"Blood"},{"key":"10269_CR122","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic, B. I., Lakhani, N., Patnaik, A., et al. (2019). First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. Journal of Clinical Oncology, 37, 946\u2013953.","journal-title":"Journal of Clinical Oncology"},{"key":"10269_CR123","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1200\/JCO.2020.38.15_suppl.3064","volume":"38","author":"A Patnaik","year":"2020","unstructured":"Patnaik, A., Spreafico, A., Paterson, A. M., et al. (2020). Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody. Journal of Clinical Oncology., 38, 3064\u20133064.","journal-title":"Journal of Clinical Oncology."},{"key":"10269_CR124","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1200\/JCO.2024.42.16_suppl.2642","volume":"42","author":"HY Lim","year":"2024","unstructured":"Lim, H. Y., Ahn, J. S., Park, J. O., et al. (2024). Updated safety, efficacy, pharmacokinetics, and biomarkers from the phase 1 study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors. Journal of Clinical Oncology., 42, 2642\u20132642.","journal-title":"Journal of Clinical Oncology."},{"key":"10269_CR125","doi-asserted-by":"publisher","first-page":"e14513","DOI":"10.1200\/JCO.2023.41.16_suppl.e14513","volume":"41","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q., Liu, A., Shi, J., et al. (2023). A first-in-human study of MIL95, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors and lymphomas. Journal of Clinical Oncology., 41, e14513\u2013e14513.","journal-title":"Journal of Clinical Oncology."},{"key":"10269_CR126","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.1238856","volume":"341","author":"K Weiskopf","year":"2013","unstructured":"Weiskopf, K., Ring, A. M., Ho, C. C., et al. (2013). Engineered SIRP\u03b1 variants as immunotherapeutic adjuvants to anticancer antibodies. Science, 341, 88\u201391.","journal-title":"Science"},{"key":"10269_CR127","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani, R., Flinn, I., Popplewell, L., et al. (2018). CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. New England Journal of Medicine, 379, 1711\u20131721.","journal-title":"New England Journal of Medicine"},{"key":"10269_CR128","doi-asserted-by":"publisher","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","volume":"10","author":"J Liu","year":"2015","unstructured":"Liu, J., Wang, L., Zhao, F., et al. (2015). Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE, 10, e0137345.","journal-title":"PLoS ONE"},{"key":"10269_CR129","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1038\/s41467-018-05211-7","volume":"9","author":"M Feng","year":"2018","unstructured":"Feng, M., Marjon, K. D., Zhu, F., et al. (2018). Programmed cell removal by calreticulin in tissue homeostasis and cancer. Nature Communications, 9, 3194.","journal-title":"Nature Communications"},{"key":"10269_CR130","doi-asserted-by":"publisher","first-page":"E5434","DOI":"10.1073\/pnas.1521069113","volume":"113","author":"Z Bian","year":"2016","unstructured":"Bian, Z., Shi, L., Guo, Y. L., et al. (2016). Cd47-Sirp\u03b1 interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells. Proc Natl Acad Sci U S A., 113, E5434-5443.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10269_CR131","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neuron.2018.09.017","volume":"100","author":"EK Lehrman","year":"2018","unstructured":"Lehrman, E. K., Wilton, D. K., Litvina, E. Y., et al. (2018). CD47 Protects Synapses from Excess Microglia-Mediated Pruning during Development. Neuron, 100, 120-134.e126.","journal-title":"Neuron"},{"key":"10269_CR132","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","volume":"52","author":"MEW Logtenberg","year":"2020","unstructured":"Logtenberg, M. E. W., Scheeren, F. A., & Schumacher, T. N. (2020). The CD47-SIRP\u03b1 Immune Checkpoint. Immunity, 52, 742\u2013752.","journal-title":"Immunity"},{"key":"10269_CR133","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/jbmr.441","volume":"26","author":"LA Maile","year":"2011","unstructured":"Maile, L. A., DeMambro, V. E., Wai, C., et al. (2011). An essential role for the association of CD47 to SHPS-1 in skeletal remodeling. Journal of Bone and Mineral Research, 26, 2068\u20132081.","journal-title":"Journal of Bone and Mineral Research"},{"key":"10269_CR134","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1038\/s41467-021-22301-1","volume":"12","author":"X Ding","year":"2021","unstructured":"Ding, X., Wang, J., Huang, M., et al. (2021). Loss of microglial SIRP\u03b1 promotes synaptic pruning in preclinical models of neurodegeneration. Nature Communications, 12, 2030.","journal-title":"Nature Communications"},{"key":"10269_CR135","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4049\/jimmunol.1100528","volume":"187","author":"M Sato-Hashimoto","year":"2011","unstructured":"Sato-Hashimoto, M., Saito, Y., Ohnishi, H., et al. (2011). Signal regulatory protein \u03b1 regulates the homeostasis of T lymphocytes in the spleen. The Journal of Immunology, 187, 291\u2013297.","journal-title":"The Journal of Immunology"},{"key":"10269_CR136","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.4049\/jimmunol.167.5.2547","volume":"167","author":"S Latour","year":"2001","unstructured":"Latour, S., Tanaka, H., Demeure, C., et al. (2001). Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: Down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation. The Journal of Immunology, 167, 2547\u20132554.","journal-title":"The Journal of Immunology"},{"key":"10269_CR137","doi-asserted-by":"crossref","unstructured":"Liu, Y., Merlin, D., Burst, S. L., Pochet, M., Madara, J. L., & Parkos, C. A. (2001). The role of CD47 in neutrophil transmigration. Increased rate of migration correlates with increased cell surface expression of CD47. J Biol Chem, 276, 40156\u201340166.","DOI":"10.1074\/jbc.M104138200"},{"key":"10269_CR138","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1182\/blood-2010-03-277244","volume":"116","author":"Y Saito","year":"2010","unstructured":"Saito, Y., Iwamura, H., Kaneko, T., et al. (2010). Regulation by SIRP\u03b1 of dendritic cell homeostasis in lymphoid tissues. Blood, 116, 3517\u20133525.","journal-title":"Blood"},{"key":"10269_CR139","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1182\/blood-2019-122793","volume":"134","author":"Z Meng","year":"2019","unstructured":"Meng, Z., Wang, Z., Guo, B., Cao, W., & Shen, H. (2019). TJC4, a differentiated anti-CD47 antibody with novel epitope and RBC sparing properties. Blood, 134, 4063.","journal-title":"Blood"},{"key":"10269_CR140","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1182\/blood-2021-150606","volume":"138","author":"A Mehta","year":"2021","unstructured":"Mehta, A., Harb, W., Xu, C., et al. (2021). Lemzoparlimab, a differentiated anti-CD47 antibody in combination with rituximab in relapsed and refractory non-Hodgkin\u2019s lymphoma: Initial clinical results. Blood, 138, 3542.","journal-title":"Blood"},{"key":"10269_CR141","doi-asserted-by":"publisher","first-page":"B100","DOI":"10.1158\/1535-7163.TARG-19-B100","volume":"18","author":"C Wilson","year":"2019","unstructured":"Wilson, C., Bouchlaka, M., Puro, R., et al. (2019). Abstract B100: AO-176, a highly differentiated humanized anti-CD47 antibody, exhibits single-agent and combination antitumor efficacy with chemotherapy and targeted antibodies. Molecular Cancer Therapeutics, 18, B100\u2013B100.","journal-title":"Molecular Cancer Therapeutics"},{"key":"10269_CR142","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1158\/1535-7163.MCT-19-1079","volume":"19","author":"RJ Puro","year":"2020","unstructured":"Puro, R. J., Bouchlaka, M. N., Hiebsch, R. R., et al. (2020). Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding. Molecular Cancer Therapeutics, 19, 835\u2013846.","journal-title":"Molecular Cancer Therapeutics"},{"key":"10269_CR143","doi-asserted-by":"crossref","unstructured":"III HAB, Spira, A. I., Taylor, M. H., et al. (2021). A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors. Journal of Clinical Oncology, 39, 2516\u20132516.","DOI":"10.1200\/JCO.2021.39.15_suppl.2516"},{"key":"10269_CR144","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.ccell.2023.10.007","volume":"41","author":"JC Osorio","year":"2023","unstructured":"Osorio, J. C., Smith, P., Knorr, D. A., & Ravetch, J. V. (2023). The antitumor activities of anti-CD47 antibodies require Fc-Fc\u03b3R interactions. Cancer Cell, 41, 2051-2065.e2056.","journal-title":"Cancer Cell"},{"key":"10269_CR145","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12951-020-0571-2","volume":"18","author":"L Ma","year":"2020","unstructured":"Ma, L., Zhu, M., Gai, J., et al. (2020). Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential. J Nanobiotechnology., 18, 12.","journal-title":"J Nanobiotechnology."},{"key":"10269_CR146","doi-asserted-by":"publisher","first-page":"5622","DOI":"10.1158\/1538-7445.AM2018-5622","volume":"78","author":"Z Wang","year":"2018","unstructured":"Wang, Z., Cao, W., Guo, T., & Zang, J. (2018). Abstract 5622: A novel immunocytokine fusion protein combining tumor-targeting anti-CD47 antibody with GM-CSF cytokine for enhanced antitumor efficacy. Cancer Research., 78, 5622\u20135622.","journal-title":"Cancer Research."},{"key":"10269_CR147","doi-asserted-by":"publisher","first-page":"7306","DOI":"10.1038\/s41467-023-42972-2","volume":"14","author":"Y Guo","year":"2023","unstructured":"Guo, Y., Bao, Q., Hu, P., & Shi, J. (2023). Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy. Nature Communications, 14, 7306.","journal-title":"Nature Communications"},{"key":"10269_CR148","first-page":"779","volume":"10","author":"JD Marks","year":"1992","unstructured":"Marks, J. D., Griffiths, A. D., Malmqvist, M., Clackson, T. P., Bye, J. M., & Winter, G. (1992). By-passing immunization: Building high affinity human antibodies by chain shuffling. Biotechnology (N. Y), 10, 779\u2013783.","journal-title":"Biotechnology (N. Y)"},{"key":"10269_CR149","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","volume":"23","author":"PS Petrova","year":"2017","unstructured":"Petrova, P. S., Viller, N. N., Wong, M., et al. (2017). TTI-621 (SIRP\u03b1Fc): A CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clinical Cancer Research, 23, 1068\u20131079.","journal-title":"Clinical Cancer Research"},{"key":"10269_CR150","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(21)00584-2","volume":"22","author":"NJ Lakhani","year":"2021","unstructured":"Lakhani, N. J., Chow, L. Q. M., Gainor, J. F., et al. (2021). Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): A first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. The lancet Oncology, 22, 1740\u20131751.","journal-title":"The lancet Oncology"},{"key":"10269_CR151","doi-asserted-by":"publisher","first-page":"e0187262","DOI":"10.1371\/journal.pone.0187262","volume":"12","author":"GHY Lin","year":"2017","unstructured":"Lin, G. H. Y., Chai, V., Lee, V., et al. (2017). TTI-621 (SIRP\u03b1Fc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. PLoS ONE, 12, e0187262.","journal-title":"PLoS ONE"},{"key":"10269_CR152","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","volume":"27","author":"SM Ansell","year":"2021","unstructured":"Ansell, S. M., Maris, M. B., Lesokhin, A. M., et al. (2021). Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clinical Cancer Research, 27, 2190\u20132199.","journal-title":"Clinical Cancer Research"},{"key":"10269_CR153","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1182\/blood-2021-154490","volume":"138","author":"SM Horwitz","year":"2021","unstructured":"Horwitz, S. M., Foran, J. M., Maris, M., et al. (2021). Updates from ongoing, first-in-human phase 1 dose escalation and expansion study of TTI-621, a novel biologic targeting CD47, in patients with relapsed or refractory hematologic malignancies. Blood, 138, 2448.","journal-title":"Blood"},{"key":"10269_CR154","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1200\/JCO.2021.39.15_suppl.2550","volume":"39","author":"M Sun","year":"2021","unstructured":"Sun, M., Qi, J., Zheng, W., et al. (2021). Preliminary results of a first-in-human phase I dtudy of IMM01, SIRP\u03b1 Fc protein in patients with relapsed or refractory lymphoma. Journal of Clinical Oncology., 39, 2550\u20132550.","journal-title":"Journal of Clinical Oncology."},{"key":"10269_CR155","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1038\/s41467-020-18245-7","volume":"11","author":"D Candas-Green","year":"2020","unstructured":"Candas-Green, D., Xie, B., Huang, J., et al. (2020). Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nature Communications, 11, 4591.","journal-title":"Nature Communications"},{"key":"10269_CR156","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.biomaterials.2017.01.004","volume":"121","author":"E Koh","year":"2017","unstructured":"Koh, E., Lee, E. J., Nam, G. H., et al. (2017). Exosome-SIRP\u03b1, a CD47 blockade increases cancer cell phagocytosis. Biomaterials, 121, 121\u2013129.","journal-title":"Biomaterials"},{"key":"10269_CR157","doi-asserted-by":"publisher","first-page":"845217","DOI":"10.3389\/fimmu.2022.845217","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu, J., Meng, Z., Xu, T., et al. (2022). A SIRP\u03b1Fc fusion protein conjugated with the collagen-binding domain for targeted immunotherapy of non-small cell lung cancer. Frontiers in Immunology, 13, 845217.","journal-title":"Frontiers in Immunology"},{"key":"10269_CR158","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ymthe.2016.11.006","volume":"25","author":"E Dheilly","year":"2017","unstructured":"Dheilly, E., Moine, V., Broyer, L., et al. (2017). Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Molecular Therapy, 25, 523\u2013533.","journal-title":"Molecular Therapy"},{"key":"10269_CR159","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1080\/19420862.2015.1062192","volume":"7","author":"EC Piccione","year":"2015","unstructured":"Piccione, E. C., Juarez, S., Liu, J., et al. (2015). A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs, 7, 946\u2013956.","journal-title":"MAbs"},{"key":"10269_CR160","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"AN Bartley","year":"2017","unstructured":"Bartley, A. N., Washington, M. K., Colasacco, C., et al. (2017). HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. Journal of Clinical Oncology, 35, 446\u2013464.","journal-title":"Journal of Clinical Oncology"},{"key":"10269_CR161","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1158\/1538-7445.AM2023-2938","volume":"83","author":"B Zhang","year":"2023","unstructured":"Zhang, B., Li, S., Chen, D., et al. (2023). Abstract 2938: Preclinical development of a novel bispecific mAb-Trap fusion protein, IMM2902, targeting both HER2 and CD47 as cancer immunotherapy. Cancer Research., 83, 2938\u20132938.","journal-title":"Cancer Research."},{"key":"10269_CR162","doi-asserted-by":"publisher","first-page":"101068","DOI":"10.1016\/j.drup.2024.101068","volume":"74","author":"B Zhang","year":"2024","unstructured":"Zhang, B., Shi, J., Shi, X., et al. (2024). Development and evaluation of a human CD47\/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy. Drug Resist Updat., 74, 101068.","journal-title":"Drug Resist Updat."},{"key":"10269_CR163","doi-asserted-by":"publisher","first-page":"e15185","DOI":"10.1200\/JCO.2023.41.16_suppl.e15185","volume":"41","author":"Y Meng","year":"2023","unstructured":"Meng, Y., Zhang, J., Zhao, C., et al. (2023). Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors. Journal of Clinical Oncology., 41, e15185\u2013e15185.","journal-title":"Journal of Clinical Oncology."},{"key":"10269_CR164","doi-asserted-by":"crossref","unstructured":"Overman, M. J., Melhem, R., Blum-Murphy, M. A., et al. (2023). A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas. Journal of Clinical Oncology, 41, TPS765-TPS765.","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS765"},{"key":"10269_CR165","doi-asserted-by":"crossref","unstructured":"Overman, M. J., Laeufle, R., Singh, H., et al. (2024). 1531TiP TWINPEAK phase I\/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and\/or pembrolizumab in gastric\/GEJ-carcinomas or PDAC. Annals of Oncology, 35, S933-S934.","DOI":"10.1016\/j.annonc.2024.08.1594"},{"key":"10269_CR166","doi-asserted-by":"crossref","unstructured":"Weidemann, S., Gagelmann, P., Gorbokon, N., et al. (2021). Mesothelin expression in human tumors: A tissue microarray study on 12,679 tumors. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040397"},{"key":"10269_CR167","first-page":"A740","volume":"10","author":"E Romano","year":"2022","unstructured":"Romano, E., Medioni, J., Rouge, T. D. L. M., et al. (2022). 707 A phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers. Journal for Immunotherapy of Cancer, 10, A740\u2013A740.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10269_CR168","doi-asserted-by":"crossref","unstructured":"Houvast, R. D., van Duijvenvoorde, M., Thijse, K., et al. (2024). Selecting targets for molecular imaging of gastric cancer: An immunohistochemical evaluation. Mol Diagn Ther.","DOI":"10.1007\/s40291-024-00755-5"},{"key":"10269_CR169","doi-asserted-by":"publisher","first-page":"1378813","DOI":"10.3389\/fimmu.2024.1378813","volume":"15","author":"A Seckinger","year":"2024","unstructured":"Seckinger, A., Buatois, V., Moine, V., et al. (2024). Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 \u03ba\u03bb bispecific antibody. Frontiers in Immunology, 15, 1378813.","journal-title":"Frontiers in Immunology"},{"key":"10269_CR170","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.ymthe.2021.01.006","volume":"29","author":"K Du","year":"2021","unstructured":"Du, K., Li, Y., Liu, J., et al. (2021). A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Molecular Therapy, 29, 1572\u20131584.","journal-title":"Molecular Therapy"},{"key":"10269_CR171","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s12672-024-01694-7","volume":"15","author":"N Yi","year":"2024","unstructured":"Yi, N., Yin, X., Feng, X., Ren, M., & Ma, C. (2024). Identification of gastric cancer subtypes based on disulfidptosis-related genes: GPC3 as a novel biomarker for prognosis prediction. Discov Oncol., 15, 810.","journal-title":"Discov Oncol."},{"key":"10269_CR172","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","volume":"76","author":"K Weiskopf","year":"2017","unstructured":"Weiskopf, K. (2017). Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis. European Journal of Cancer, 76, 100\u2013109.","journal-title":"European Journal of Cancer"},{"key":"10269_CR173","doi-asserted-by":"crossref","unstructured":"Liu, J., Xavy, S., Mihardja, S., et al. (2020). Targeting macrophage checkpoint inhibitor SIRP\u03b1 for anticancer therapy. JCI Insight, 5.","DOI":"10.1172\/jci.insight.134728"},{"key":"10269_CR174","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","volume":"11","author":"EJ Brown","year":"2001","unstructured":"Brown, E. J., & Frazier, W. A. (2001). Integrin-associated protein (CD47) and its ligands. Trends in Cell Biology, 11, 130\u2013135.","journal-title":"Trends in Cell Biology"},{"key":"10269_CR175","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41467-021-23442-z","volume":"12","author":"Z Bian","year":"2021","unstructured":"Bian, Z., Shi, L., Kidder, K., Zen, K., Garnett-Benson, C., & Liu, Y. (2021). Intratumoral SIRP\u03b1-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy. Nature Communications, 12, 3229.","journal-title":"Nature Communications"},{"key":"10269_CR176","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1172\/JCI135528","volume":"130","author":"V Gauttier","year":"2020","unstructured":"Gauttier, V., Pengam, S., Durand, J., et al. (2020). Selective SIRP\u03b1 blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance. The Journal of Clinical Investigation, 130, 6109\u20136123.","journal-title":"The Journal of Clinical Investigation"},{"key":"10269_CR177","doi-asserted-by":"publisher","first-page":"E10578","DOI":"10.1073\/pnas.1710877114","volume":"114","author":"NG Ring","year":"2017","unstructured":"Ring, N. G., Herndler-Brandstetter, D., Weiskopf, K., et al. (2017). Anti-SIRP\u03b1 antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A., 114, E10578-e10585.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10269_CR178","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood-2021-147262","volume":"138","author":"H Chan","year":"2021","unstructured":"Chan, H., Trout, C., Mikolon, D., et al. (2021). Discovery and preclinical characterization of CC-95251, an Anti-SIRP\u03b1 antibody that enhances macrophage-mediated phagocytosis of non-Hodgkin lymphoma (NHL) cells when combined with rituximab. Blood, 138, 2271\u20132271.","journal-title":"Blood"},{"key":"10269_CR179","doi-asserted-by":"publisher","first-page":"e0304985","DOI":"10.1371\/journal.pone.0304985","volume":"19","author":"M Sue","year":"2024","unstructured":"Sue, M., Tsubaki, T., Ishimoto, Y., et al. (2024). Blockade of SIRP\u03b1-CD47 axis by anti-SIRP\u03b1 antibody enhances anti-tumor activity of DXd antibody-drug conjugates. PLoS ONE, 19, e0304985.","journal-title":"PLoS ONE"},{"key":"10269_CR180","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41591-019-0356-z","volume":"25","author":"MEW Logtenberg","year":"2019","unstructured":"Logtenberg, M. E. W., Jansen, J. H. M., Raaben, M., et al. (2019). Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRP\u03b1 axis and a target for cancer immunotherapy. Nature Medicine, 25, 612\u2013619.","journal-title":"Nature Medicine"},{"key":"10269_CR181","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41422-019-0177-0","volume":"29","author":"Z Wu","year":"2019","unstructured":"Wu, Z., Weng, L., Zhang, T., et al. (2019). Identification of glutaminyl cyclase isoenzyme isoQC as a regulator of SIRP\u03b1-CD47 axis. Cell Research, 29, 502\u2013505.","journal-title":"Cell Research"},{"key":"10269_CR182","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.jmb.2008.03.078","volume":"379","author":"H Cynis","year":"2008","unstructured":"Cynis, H., Rahfeld, J. U., Stephan, A., et al. (2008). Isolation of an isoenzyme of human glutaminyl cyclase: Retention in the Golgi complex suggests involvement in the protein maturation machinery. Journal of Molecular Biology, 379, 966\u2013980.","journal-title":"Journal of Molecular Biology"},{"key":"10269_CR183","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.trci.2015.08.002","volume":"1","author":"I Lues","year":"2015","unstructured":"Lues, I., Weber, F., Meyer, A., et al. (2015). A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects. Alzheimers Dement (N Y)., 1, 182\u2013195.","journal-title":"Alzheimers Dement (N Y)."},{"key":"10269_CR184","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13195-018-0431-6","volume":"10","author":"P Scheltens","year":"2018","unstructured":"Scheltens, P., Hallikainen, M., Grimmer, T., et al. (2018). Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer\u2019s disease: Results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers Res Ther., 10, 107.","journal-title":"Alzheimers Res Ther."},{"key":"10269_CR185","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1200\/JCO.2023.41.16_suppl.2600","volume":"41","author":"Z Song","year":"2023","unstructured":"Song, Z., Tong, X., Zhang, Y., et al. (2023). IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma: An open-label, multicenter, phase 1b\/2 dose escalation and expansion study (IMM01-04). Journal of Clinical Oncology., 41, 2600\u20132600.","journal-title":"Journal of Clinical Oncology."},{"key":"10269_CR186","doi-asserted-by":"publisher","first-page":"18342","DOI":"10.1073\/pnas.1106550108","volume":"108","author":"XW Zhao","year":"2011","unstructured":"Zhao, X. W., van Beek, E. M., Schornagel, K., et al. (2011). CD47-signal regulatory protein-\u03b1 (SIRP\u03b1) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A., 108, 18342\u201318347.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10269_CR187","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/eji.201747215","volume":"48","author":"LW Treffers","year":"2018","unstructured":"Treffers, L. W., Zhao, X. W., van der Heijden, J., et al. (2018). Genetic variation of human neutrophil Fc\u03b3 receptors and SIRP\u03b1 in antibody-dependent cellular cytotoxicity towards cancer cells. European Journal of Immunology, 48, 344\u2013354.","journal-title":"European Journal of Immunology"},{"key":"10269_CR188","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J., Van Cutsem, E., Feyereislova, A., et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet, 376, 687\u2013697.","journal-title":"Lancet"},{"key":"10269_CR189","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick, F., Carneiro, F., Cascinu, S., et al. (2022). Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of Oncology, 33, 1005\u20131020.","journal-title":"Annals of Oncology"},{"key":"10269_CR190","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1056\/NEJMc2408121","volume":"391","author":"YY Janjigian","year":"2024","unstructured":"Janjigian, Y. Y., Kawazoe, A., Bai, Y., et al. (2024). Pembrolizumab in HER2-positive gastric cancer. New England Journal of Medicine, 391, 1360\u20131362.","journal-title":"New England Journal of Medicine"},{"key":"10269_CR191","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1016\/j.celrep.2018.05.082","volume":"23","author":"HL Matlung","year":"2018","unstructured":"Matlung, H. L., Babes, L., Zhao, X. W., et al. (2018). Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Reports, 23, 3946-3959.e3946.","journal-title":"Cell Reports"},{"key":"10269_CR192","doi-asserted-by":"publisher","first-page":"e0201832","DOI":"10.1371\/journal.pone.0201832","volume":"13","author":"SE Kauder","year":"2018","unstructured":"Kauder, S. E., Kuo, T. C., Harrabi, O., et al. (2018). ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS ONE, 13, e0201832.","journal-title":"PLoS ONE"},{"key":"10269_CR193","doi-asserted-by":"crossref","unstructured":"Upton, R., Banuelos, A., Feng, D., et al. (2021). Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A, 118.","DOI":"10.1073\/pnas.2026849118"},{"key":"10269_CR194","doi-asserted-by":"crossref","unstructured":"Tsao, L. C., Crosby, E. J., Trotter, T. N., et al. (2019). CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. JCI Insight, 4.","DOI":"10.1172\/jci.insight.131882"},{"key":"10269_CR195","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.2020.38.15_suppl.3056","volume":"38","author":"LQM Chow","year":"2020","unstructured":"Chow, L. Q. M., Gainor, J. F., Lakhani, N. J., et al. (2020). A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy. Journal of Clinical Oncology., 38, 3056\u20133056.","journal-title":"Journal of Clinical Oncology."},{"key":"10269_CR196","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1200\/JCO.19.03077","volume":"38","author":"A Makiyama","year":"2020","unstructured":"Makiyama, A., Sukawa, Y., Kashiwada, T., et al. (2020). Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study). Journal of Clinical Oncology, 38, 1919\u20131927.","journal-title":"Journal of Clinical Oncology"},{"key":"10269_CR197","doi-asserted-by":"publisher","first-page":"S215","DOI":"10.1016\/j.annonc.2021.05.055","volume":"32","author":"H Chung","year":"2021","unstructured":"Chung, H., Lee, K., Kim, W., et al. (2021). SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer. Annals of Oncology., 32, S215\u2013S216.","journal-title":"Annals of Oncology."},{"key":"10269_CR198","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","volume":"22","author":"S Seo","year":"2019","unstructured":"Seo, S., Ryu, M. H., Park, Y. S., et al. (2019). Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer, 22, 527\u2013535.","journal-title":"Gastric Cancer"},{"key":"10269_CR199","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2018.09.024","volume":"105","author":"H Saeki","year":"2018","unstructured":"Saeki, H., Oki, E., Kashiwada, T., et al. (2018). Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). European Journal of Cancer, 105, 41\u201349.","journal-title":"European Journal of Cancer"},{"key":"10269_CR200","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke, H., Muro, K., Van Cutsem, E., et al. (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. The lancet Oncology, 15, 1224\u20131235.","journal-title":"The lancet Oncology"},{"key":"10269_CR201","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","volume":"14","author":"F Lordick","year":"2013","unstructured":"Lordick, F., Kang, Y. K., Chung, H. C., et al. (2013). Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial. The lancet Oncology, 14, 490\u2013499.","journal-title":"The lancet Oncology"},{"key":"10269_CR202","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S1470-2045(14)70024-5","volume":"15","author":"SJ Dutton","year":"2014","unstructured":"Dutton, S. J., Ferry, D. R., Blazeby, J. M., et al. (2014). Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial. The lancet Oncology, 15, 894\u2013904.","journal-title":"The lancet Oncology"},{"key":"10269_CR203","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","volume":"14","author":"T Waddell","year":"2013","unstructured":"Waddell, T., Chau, I., Cunningham, D., et al. (2013). Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. The lancet Oncology, 14, 481\u2013489.","journal-title":"The lancet Oncology"},{"key":"10269_CR204","doi-asserted-by":"crossref","unstructured":"Lordick, F., Kang, Y.-K., Salman, P., et al. Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. Journal of Clinical Oncology 31, 4021\u20134021.","DOI":"10.1200\/jco.2013.31.15_suppl.4021"},{"key":"10269_CR205","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1200\/JCO.2016.70.3934","volume":"35","author":"RD Petty","year":"2017","unstructured":"Petty, R. D., Dahle-Smith, A., Stevenson, D. A. J., et al. (2017). Gefitinib and EGFR gene copy number aberrations in esophageal cancer. Journal of Clinical Oncology, 35, 2279\u20132287.","journal-title":"Journal of Clinical Oncology"},{"key":"10269_CR206","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1200\/JCO.21.02453","volume":"40","author":"SB Maron","year":"2022","unstructured":"Maron, S. B., Moya, S., Morano, F., et al. (2022). Epidermal growth factor receptor inhibition in epidermal growth factor receptor-amplified gastroesophageal cancer: Retrospective global experience. Journal of Clinical Oncology, 40, 2458\u20132467.","journal-title":"Journal of Clinical Oncology"},{"key":"10269_CR207","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1158\/1078-0432.CCR-20-0121","volume":"27","author":"S Corso","year":"2021","unstructured":"Corso, S., Pietrantonio, F., Apicella, M., et al. (2021). Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas. Clinical Cancer Research, 27, 3126\u20133140.","journal-title":"Clinical Cancer Research"},{"key":"10269_CR208","doi-asserted-by":"crossref","unstructured":"Li, B., Hao, Y., He, H., et al. (2024). CD47-SIRP\u03b1 blockade sensitizes head and neck squamous cell carcinoma to cetuximab by enhancing macrophage adhesion to cancer cells. Cancer Res.","DOI":"10.1158\/0008-5472.c.7474573"},{"key":"10269_CR209","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1200\/JCO.2020.38.4_suppl.114","volume":"38","author":"GA Fisher","year":"2020","unstructured":"Fisher, G. A., Lakhani, N. J., Eng, C., et al. (2020). A phase Ib\/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. Journal of Clinical Oncology., 38, 114\u2013114.","journal-title":"Journal of Clinical Oncology."},{"key":"10269_CR210","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","volume":"23","author":"ZA Wainberg","year":"2022","unstructured":"Wainberg, Z. A., Enzinger, P. C., Kang, Y. K., et al. (2022). Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): A randomised, double-blind, placebo-controlled, phase 2 study. The lancet Oncology, 23, 1430\u20131440.","journal-title":"The lancet Oncology"},{"key":"10269_CR211","doi-asserted-by":"publisher","first-page":"e2400710","DOI":"10.1200\/PO-24-00710","volume":"9","author":"SY Rha","year":"2025","unstructured":"Rha, S. Y., Zhang, Y., Elme, A., et al. (2025). Prevalence of FGFR2b protein overexpression in advanced gastric cancers during prescreening for the phase III FORTITUDE-101 Trial. JCO Precision Oncology, 9, e2400710.","journal-title":"JCO Precision Oncology"},{"key":"10269_CR212","doi-asserted-by":"publisher","first-page":"e15074","DOI":"10.1200\/jco.2014.32.15_suppl.e15074","volume":"32","author":"KL Pierce","year":"2014","unstructured":"Pierce, K. L., Deshpande, A. M., Stohr, B. A., et al. (2014). FPA144, a humanized monoclonal antibody for both <i>FGFR2<\/i>-amplified and nonamplified, <i>FGFR2b<\/i>-overexpressing gastric cancer patients. Journal of Clinical Oncology., 32, e15074\u2013e15074.","journal-title":"Journal of Clinical Oncology."},{"key":"10269_CR213","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1158\/1538-7445.AM2016-1407","volume":"76","author":"J Powers","year":"2016","unstructured":"Powers, J., Palencia, S., Foy, S., et al. (2016). Abstract 1407: FPA144, a therapeutic monoclonal antibody targeting the FGFR2b receptor, promotes antibody dependent cell-mediated cytotoxicity and stimulates sensitivity to PD-1 in the 4T1 syngeneic tumor model. Cancer Research., 76, 1407\u20131407.","journal-title":"Cancer Research."},{"key":"10269_CR214","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","volume":"100","author":"U Sahin","year":"2018","unstructured":"Sahin, U., Schuler, M., Richly, H., et al. (2018). A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. European Journal of Cancer, 100, 17\u201326.","journal-title":"European Journal of Cancer"},{"key":"10269_CR215","doi-asserted-by":"crossref","unstructured":"Shitara, K., Lordick, F., Bang, Y. J., et al. (2023). Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial. Lancet, 401, 1655\u20131668.","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"10269_CR216","doi-asserted-by":"crossref","unstructured":"Shah, M. A., Shitara, K., Ajani, J. A., et al. (2023). Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial. Nat Med 29, 2133\u20132141.","DOI":"10.1038\/s41591-023-02465-7"},{"key":"10269_CR217","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJMc2409512","volume":"391","author":"K Shitara","year":"2024","unstructured":"Shitara, K., Shah, M. A., Lordick, F., et al. (2024). Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. New England Journal of Medicine, 391, 1159\u20131162.","journal-title":"New England Journal of Medicine"},{"key":"10269_CR218","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","volume":"22","author":"AA Getu","year":"2023","unstructured":"Getu, A. A., Tigabu, A., Zhou, M., Lu, J., Fodstad, \u00d8., & Tan, M. (2023). New frontiers in immune checkpoint B7\u2013H3 (CD276) research and drug development. Molecular Cancer, 22, 43.","journal-title":"Molecular Cancer"},{"key":"10269_CR219","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","volume":"56","author":"R Singh","year":"2024","unstructured":"Singh, R., Kim, Y. H., Lee, S. J., Eom, H. S., & Choi, B. K. (2024). 4\u20131BB immunotherapy: Advances and hurdles. Experimental & Molecular Medicine, 56, 32\u201339.","journal-title":"Experimental & Molecular Medicine"},{"key":"10269_CR220","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.3727\/096504017X14900505020895","volume":"25","author":"H Tao","year":"2017","unstructured":"Tao, H., Qian, P., Wang, F., Yu, H., & Guo, Y. (2017). Targeting CD47 enhances the efficacy of anti-PD-1 and CTLA-4 in an esophageal squamous cell cancer preclinical model. Oncology Research, 25, 1579\u20131587.","journal-title":"Oncology Research"},{"key":"10269_CR221","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12, 252\u2013264.","journal-title":"Nature Reviews Cancer"},{"key":"10269_CR222","doi-asserted-by":"publisher","first-page":"2005344","DOI":"10.1080\/2162402X.2021.2005344","volume":"10","author":"M Hendriks","year":"2021","unstructured":"Hendriks, M., Britsch, I., Ke, X., et al. (2021). Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRP\u03b1 axis. Oncoimmunology., 10, 2005344.","journal-title":"Oncoimmunology."},{"key":"10269_CR223","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso, R. T., Pope, H. W., Zimmer, M. D., et al. (2017). In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature, 547, 413\u2013418.","journal-title":"Nature"},{"key":"10269_CR224","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.celrep.2018.07.062","volume":"24","author":"X Liu","year":"2018","unstructured":"Liu, X., Liu, L., Ren, Z., et al. (2018). Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion. Cell Reports, 24, 2101\u20132111.","journal-title":"Cell Reports"},{"key":"10269_CR225","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ebiom.2019.03.018","volume":"42","author":"S Lian","year":"2019","unstructured":"Lian, S., Xie, R., Ye, Y., et al. (2019). Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. eBioMedicine, 42, 281\u2013295.","journal-title":"eBioMedicine"},{"key":"10269_CR226","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1158\/1538-7445.AM2018-3852","volume":"78","author":"G Daginakatte","year":"2018","unstructured":"Daginakatte, G., Pottayil, S., Chennakrishna, G., et al. (2018). Abstract 3852: Combination efficacy and safety profile of an orally bioavailable small molecule agent targeting CD47\/SIRP\u03b1 axis. Cancer Research., 78, 3852\u20133852.","journal-title":"Cancer Research."},{"key":"10269_CR227","doi-asserted-by":"publisher","first-page":"e89140","DOI":"10.1172\/jci.insight.89140","volume":"2","author":"T Yanagita","year":"2017","unstructured":"Yanagita, T., Murata, Y., Tanaka, D., et al. (2017). Anti-SIRP\u03b1 antibodies as a potential new tool for cancer immunotherapy. JCI Insight., 2, e89140.","journal-title":"JCI Insight."},{"key":"10269_CR228","doi-asserted-by":"crossref","unstructured":"Chen, S. H., Dominik, P. K., Stanfield, J., et al. (2021). Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. J Immunother Cancer, 9.","DOI":"10.1136\/jitc-2021-003464"},{"key":"10269_CR229","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng, L., Liang, H., Xu, M., et al. (2014). STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity, 41, 843\u2013852.","journal-title":"Immunity"},{"key":"10269_CR230","doi-asserted-by":"publisher","first-page":"148","DOI":"10.7150\/thno.79367","volume":"13","author":"R Wang","year":"2023","unstructured":"Wang, R., Zhang, C., Cao, Y., et al. (2023). Blockade of dual immune checkpoint inhibitory signals with a CD47\/PD-L1 bispecific antibody for cancer treatment. Theranostics., 13, 148\u2013160.","journal-title":"Theranostics."},{"key":"10269_CR231","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00262-020-02679-5","volume":"70","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Ni, H., Zhou, S., et al. (2021). Tumor-selective blockade of CD47 signaling with a CD47\/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. Cancer Immunology, Immunotherapy, 70, 365\u2013376.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10269_CR232","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1200\/JCO.2021.39.15_suppl.2517","volume":"39","author":"A Roohullah","year":"2021","unstructured":"Roohullah, A., Ganju, V., Zhang, F., et al. (2021). First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies. Journal of Clinical Oncology., 39, 2517\u20132517.","journal-title":"Journal of Clinical Oncology."},{"key":"10269_CR233","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1200\/JCO.2023.41.16_suppl.2529","volume":"41","author":"BA Carneiro","year":"2023","unstructured":"Carneiro, B. A., Safran, H., Beck, J. T. T., et al. (2023). Phase 1 first-in-human study of PF-07257876, a novel CD47\/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1\/PD-L1-refractory and -na\u00efve advanced solid tumors. Journal of Clinical Oncology., 41, 2529\u20132529.","journal-title":"Journal of Clinical Oncology."},{"key":"10269_CR234","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359, 1350\u20131355.","journal-title":"Science"},{"key":"10269_CR235","first-page":"3301","volume":"20","author":"X Song","year":"2020","unstructured":"Song, X., Lu, Z., & Xu, J. (2020). Targeting cluster of differentiation 47 improves the efficacy of anti-cytotoxic T-lymphocyte associated protein 4 treatment via antigen presentation enhancement in pancreatic ductal adenocarcinoma. Experimental and Therapeutic Medicine, 20, 3301\u20133309.","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10269_CR236","doi-asserted-by":"publisher","first-page":"e16050","DOI":"10.1200\/JCO.2023.41.16_suppl.e16050","volume":"41","author":"Q Xia","year":"2023","unstructured":"Xia, Q., Wu, T., Wang, F., et al. (2023). The safety and efficacy of cadonilimab in combination with AK117 (anti-CD47 antibody) plus chemotherapy as first-line treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer. Journal of Clinical Oncology., 41, e16050\u2013e16050.","journal-title":"Journal of Clinical Oncology."},{"key":"10269_CR237","doi-asserted-by":"crossref","unstructured":"Zhang, A., Ren, Z., Tseng, K. F., et al. (2021). Dual targeting of CTLA-4 and CD47 on T(reg) cells promotes immunity against solid tumors. Sci Transl Med, 13.","DOI":"10.1126\/scitranslmed.abg8693"},{"key":"10269_CR238","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","volume":"19","author":"AA Barkal","year":"2018","unstructured":"Barkal, A. A., Weiskopf, K., Kao, K. S., et al. (2018). Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology, 19, 76\u201384.","journal-title":"Nature Immunology"},{"key":"10269_CR239","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal, A. A., Brewer, R. E., Markovic, M., et al. (2019). CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature, 572, 392\u2013396.","journal-title":"Nature"},{"key":"10269_CR240","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1038\/s41467-024-49825-6","volume":"15","author":"W Zhang","year":"2024","unstructured":"Zhang, W., Zeng, Y., Xiao, Q., et al. (2024). An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses. Nature Communications, 15, 5670.","journal-title":"Nature Communications"},{"key":"10269_CR241","doi-asserted-by":"publisher","first-page":"A076","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR18-A076","volume":"7","author":"YM Gozlan","year":"2019","unstructured":"Gozlan, Y. M., Hilgendorf, S., Aronin, A., et al. (2019). Abstract A076: DSP107\u2014a novel SIRP\u03b1-4-1BBL dual signaling protein (DSP) for cancer immunotherapy. Cancer Immunology Research, 7, A076\u2013A076.","journal-title":"Cancer Immunology Research"},{"key":"10269_CR242","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.annonc.2024.05.062","volume":"35","author":"A Saeed","year":"2024","unstructured":"Saeed, A., Zhang, J., Bashir, B., et al. (2024). 51P Phase II dose expansion study of DSP107, a first-in-class fusion protein targeting CD47 and 4\u20131BB, in combination with atezolizumab in patients with advanced MSS colorectal cancer. Annals of Oncology., 35, S25.","journal-title":"Annals of Oncology."},{"key":"10269_CR243","doi-asserted-by":"crossref","unstructured":"Gao, J., Wang, Z., Jiang, W., et al. (2023). CLDN18.2 and 4\u20131BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation. J Immunother Cancer, 11.","DOI":"10.1136\/jitc-2023-006704"},{"key":"10269_CR244","doi-asserted-by":"publisher","first-page":"111605","DOI":"10.1016\/j.biopha.2021.111605","volume":"139","author":"Y Chen","year":"2021","unstructured":"Chen, Y., Yu, Z., Tan, X., et al. (2021). CAR-macrophage: A new immunotherapy candidate against solid tumors. Biomedicine & Pharmacotherapy, 139, 111605.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10269_CR245","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1186\/s12967-023-04479-8","volume":"21","author":"Y Chen","year":"2023","unstructured":"Chen, Y., Zhu, X., Liu, H., et al. (2023). The application of HER2 and CD47 CAR-macrophage in ovarian cancer. Journal of Translational Medicine, 21, 654.","journal-title":"Journal of Translational Medicine"},{"key":"10269_CR246","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fimmu.2020.00018","volume":"11","author":"W Zhang","year":"2020","unstructured":"Zhang, W., Huang, Q., Xiao, W., et al. (2020). Advances in anti-tumor treatments targeting the CD47\/SIRP\u03b1 axis. Frontiers in Immunology, 11, 18.","journal-title":"Frontiers in Immunology"},{"key":"10269_CR247","doi-asserted-by":"publisher","first-page":"6569","DOI":"10.1038\/s41467-023-42303-5","volume":"14","author":"CW Chou","year":"2023","unstructured":"Chou, C. W., Hung, C. N., Chiu, C. H., et al. (2023). Phagocytosis-initiated tumor hybrid cells acquire a c-Myc-mediated quasi-polarization state for immunoevasion and distant dissemination. Nature Communications, 14, 6569.","journal-title":"Nature Communications"},{"key":"10269_CR248","doi-asserted-by":"publisher","first-page":"1773204","DOI":"10.1080\/2162402X.2020.1773204","volume":"9","author":"LA Aguirre","year":"2020","unstructured":"Aguirre, L. A., Montalb\u00e1n-Hern\u00e1ndez, K., Avenda\u00f1o-Ortiz, J., et al. (2020). Tumor stem cells fuse with monocytes to form highly invasive tumor-hybrid cells. Oncoimmunology., 9, 1773204.","journal-title":"Oncoimmunology."},{"key":"10269_CR249","doi-asserted-by":"crossref","unstructured":"Sutton, T. L., Patel, R. K., Anderson, A. N., et al. (2022). Circulating cells with macrophage-like characteristics in cancer: The importance of circulating neoplastic-immune hybrid cells in cancer. Cancers (Basel), 14.","DOI":"10.3390\/cancers14163871"},{"key":"10269_CR250","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","volume":"13","author":"J Yu","year":"2020","unstructured":"Yu, J., Song, Y., & Tian, W. (2020). How to select IgG subclasses in developing anti-tumor therapeutic antibodies. Journal of Hematology & Oncology, 13, 45.","journal-title":"Journal of Hematology & Oncology"},{"key":"10269_CR251","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.21037\/atm-22-5351","volume":"10","author":"F Zheng","year":"2022","unstructured":"Zheng, F., Zhang, W., Yang, B., & Chen, M. (2022). Multi-omics profiling identifies C1QA\/B(+) macrophages with multiple immune checkpoints associated with esophageal squamous cell carcinoma (ESCC) liver metastasis. Ann Transl Med., 10, 1249.","journal-title":"Ann Transl Med."},{"key":"10269_CR252","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s43018-023-00691-z","volume":"5","author":"C Huang","year":"2024","unstructured":"Huang, C., Wang, X., Wang, Y., et al. (2024). Sirp\u03b1 on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47. Nat Cancer., 5, 500\u2013516.","journal-title":"Nat Cancer."},{"key":"10269_CR253","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrg3899","volume":"16","author":"O Shalem","year":"2015","unstructured":"Shalem, O., Sanjana, N. E., & Zhang, F. (2015). High-throughput functional genomics using CRISPR-Cas9. Nature Reviews Genetics, 16, 299\u2013311.","journal-title":"Nature Reviews Genetics"},{"key":"10269_CR254","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41551-019-0454-8","volume":"3","author":"B Mair","year":"2019","unstructured":"Mair, B., Aldridge, P. M., Atwal, R. S., et al. (2019). High-throughput genome-wide phenotypic screening via immunomagnetic cell sorting. Nat Biomed Eng., 3, 796\u2013805.","journal-title":"Nat Biomed Eng."},{"key":"10269_CR255","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1038\/s41467-024-50136-z","volume":"15","author":"H Zhou","year":"2024","unstructured":"Zhou, H., Wang, W., Xu, H., et al. (2024). Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRP\u03b1 blockade efficacy. Nature Communications, 15, 5759.","journal-title":"Nature Communications"},{"key":"10269_CR256","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1074\/jbc.274.2.559","volume":"274","author":"P Jiang","year":"1999","unstructured":"Jiang, P., Lagenaur, C. F., & Narayanan, V. (1999). Integrin-associated protein is a ligand for the P84 neural adhesion molecule. Journal of Biological Chemistry, 274, 559\u2013562.","journal-title":"Journal of Biological Chemistry"},{"key":"10269_CR257","first-page":"1","volume":"423","author":"S Bournazos","year":"2019","unstructured":"Bournazos, S. (2019). IgG Fc receptors: Evolutionary considerations. Current Topics in Microbiology and Immunology, 423, 1\u201311.","journal-title":"Current Topics in Microbiology and Immunology"},{"key":"10269_CR258","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1182\/blood-2005-04-1463","volume":"107","author":"S Subramanian","year":"2006","unstructured":"Subramanian, S., Parthasarathy, R., Sen, S., Boder, E. T., & Discher, D. E. (2006). Species- and cell type-specific interactions between CD47 and human SIRPalpha. Blood, 107, 2548\u20132556.","journal-title":"Blood"},{"key":"10269_CR259","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.exphem.2013.11.005","volume":"42","author":"C Iwamoto","year":"2014","unstructured":"Iwamoto, C., Takenaka, K., Urata, S., et al. (2014). The BALB\/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment. Experimental Hematology, 42, 163-171.e161.","journal-title":"Experimental Hematology"},{"key":"10269_CR260","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1073\/pnas.1121629109","volume":"109","author":"B Edris","year":"2012","unstructured":"Edris, B., Weiskopf, K., Volkmer, A. K., et al. (2012). Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A., 109, 6656\u20136661.","journal-title":"Proc Natl Acad Sci U S A."}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10269-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-025-10269-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10269-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T10:04:21Z","timestamp":1751018661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-025-10269-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":260,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["10269"],"URL":"https:\/\/doi.org\/10.1007\/s10555-025-10269-z","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}